inc280
Showing 1 - 19 of 19
Advanced Hepatocellular Carcinoma With c-MET Dysregulation Trial in Worldwide (INC280)
Active, not recruiting
- Advanced Hepatocellular Carcinoma With c-MET Dysregulation
- INC280
-
Nanjing, Jiangsu, China
- +7 more
Jan 12, 2023
Kidney Cancer Trial run by the NCI (INC280)
Completed
- Kidney Cancer
- INC280
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 18, 2021
Recurrent NSCLC Trial in Sacramento, San Francisco (INC280, erlotinib HCl)
Completed
- Recurrent Non-small Cell Lung Cancer
- INC280
- erlotinib hydrochloride
-
Sacramento, California
- +1 more
Oct 11, 2021
Non Small Cell Lung Cancer Trial in Worldwide (EGF816, INC280, Nivolumab)
Advanced Hepatocellular Carcinoma Trial in Worldwide (PDR001, INC280)
Completed
- Advanced Hepatocellular Carcinoma
- PDR001
- INC280
-
Toronto, Ontario, Canada
- +16 more
Jul 29, 2021
EGFR-mutant NSCLC Trial in Worldwide (EGF816, trametinib, ribociclib)
Active, not recruiting
- EGFR-mutant Non-small Cell Lung Cancer
- EGF816
- +5 more
-
Toronto, Ontario, Canada
- +10 more
Dec 5, 2022
Advanced Solid Tumor Trial in Kashiwa, Fukuoka (INC280)
Completed
- Advanced Solid Tumor
- INC280
-
Kashiwa, Chiba, Japan
- +1 more
Dec 16, 2020
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma Trial in Guangzhou (BYL719, INC280, LDK378)
Completed
- Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
- BYL719
- +3 more
-
Guangzhou, Guangdong, ChinaNovartis Investigative Site
Nov 20, 2020
Hepatic Impairment Trial in United States (INC280)
Completed
- Hepatic Impairment
- INC280
-
Miami, Florida
- +4 more
Dec 8, 2020
cMET Dysegulation Advanced Solid Tumors Trial in Worldwide (INC280)
Completed
- cMET Dysegulation Advanced Solid Tumors
- INC280
-
Indianapolis, Indiana
- +16 more
Dec 16, 2020
cMET-dysregulated Advanced Solid Tumors Trial in Worldwide (INC280, Midazolam, Caffeine)
Completed
- cMET-dysregulated Advanced Solid Tumors
- INC280
- +2 more
-
Atlanta, Georgia
- +11 more
Dec 8, 2020
cMET-dysregulated Advanced Solid Tumors Trial in Worldwide (INC280, digoxin, rosuvastatin)
Completed
- cMET-dysregulated Advanced Solid Tumors
- INC280
- +2 more
-
Atlanta, Georgia
- +14 more
Dec 8, 2020
NSCLC Trial in Worldwide (INC280, Gefitinib)
Completed
- Non-small Cell Lung Cancer
- INC280
- Gefitinib
-
Woolloongabba, Queensland, Australia
- +30 more
Mar 12, 2021
Solid Tumors Trial in Worldwide (INC280)
Completed
- Solid Tumors
- INC280
-
Fayetteville, Arkansas
- +46 more
Dec 16, 2020
Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer Trial in Worldwide (INC280, cetuximab)
Terminated
- Squamous Cell Carcinoma of Head and Neck (SCCHN)
- Metastatic Colorectal Cancer
- INC280
- cetuximab
-
Boston, Massachusetts
- +14 more
Jan 17, 2019
Carcinoma, Non-Small-Cell Lung Cancer Trial (INC280)
Withdrawn
- Carcinoma
- Non-Small-Cell Lung Cancer
- INC280
- (no location specified)
Jul 24, 2018
c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280,
Terminated
- c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
- INC280
- Buparlisib
-
Boston, Massachusetts
- +12 more
May 29, 2018
Advanced Hepatocellular Carcinoma Trial in Worldwide (INC280, Placebo)
Withdrawn
- Advanced Hepatocellular Carcinoma
- INC280
- Placebo
-
Boston, Massachusetts
- +14 more
Aug 30, 2016